---

Highlights of March 2024

 

1.     Mankind Pharma enters exclusive pact to distribute AstraZeneca's anti-asthma drug Symbicort in India.

2.     Dr. Reddy's enters exclusive distribution partnership with Sanofi for their vaccine brands in India.

3.     Biocon Biologics, Eris Lifesciences announce long-term collaboration to expand patient access to metabolic, oncology, critical care products.

4.     Sanofi India, Emcure announce distribution partnership to broaden reach of cardiovascular brands.

5.     Dr. Reddy's inks license agreement with Pharmazz to commercialize Centhaquine (Lyfaquin) in India.

6.     Cipla & Sanofi partner to boost CNS portfolio in India.

7.     Mankind Pharma, in partnership with ChrysCapital, is considering a bid for Healthium Medtech, a surgical supplies company owned by Apax Partners.

8.     AstraZeneca to buy Amolyt Pharma for US$1.05 Billion to boost rare-disease portfolio.

9.     Novo Nordisk has agreed to acquire Cardior for up to EUR 1.025 Billion (~US$1.10 Billion).

10.  Bayer and Aignostics to collaborate on next generation precision oncology.

11.  BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe.

12.  Vicore enters license agreement with Nippon Shinyaku.

 

Aagami Updates:

 

1.     New Client Win: US based clinical stage Biopharma advancing the next generation novel Peptide Therapies for Inflammation.

2.     Aagami's CEO, Dinesh Jain, successfully completed DCAT week in New York City, 18+ fruitful one-on-one meetings with decision makers worldwide.

3.     Aagami will be attending the BIO International Convention 2024 in San Diego (June 3-6), and the partnering system for scheduling meetings is now open. Please submit meeting requests through the partnering system.

INFOCUS: Select opportunities available:

For Partnering/Licensing/ Co-development:

1. Seeking Strategic Partnering: Human-derived, chimeric therapeutic peptide. Phase 2b completed on Atopic Dermatitis. Novel well understood MoA. Strong patent position supportive of various multi-billion- dollar markets and multiple applications.

2.     Licensing available for Japan: Market ready Denosumab biosimilar to PROLIA^® & XGEVA^®. Other high potential Biosimilars are also available for multiple regions.

3.     Partnering/Licensing: IP for a small molecule NSAID combination for Migraine and other indications using 505(b)(2).

4.     Seeking Acquisition /JV – Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial of 30 patients ongoing in AU).

5.     Seeking Licensing/Co-development:  A phase 2 (USA) stage Tizanidine patch using proprietary ILTS technology for management of spasticity from Japanese client.

For Acquisition:

1.    Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc.- for Next-generation biologics and substantial returns.

2.     IP/Asset sale: A small molecule NSAID combination for Migraine and other indications using 505(b)(2).

3.     Asset sale - US client’s Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial of 30 patients ongoing in AU).

Seeking Investment:

1. Seeking Investment: Human-derived, chimeric therapeutic peptide. Phase 2b completed on Atopic Dermatitis. Novel well understood MoA. Strong patent position supportive of various multi-billion- dollar markets and multiple applications.
2. Seeking US$15 million: Nose to brain technology development company targeting orphan diseases such as FrontoTemporal Dementia (FTD), Alzheimer’s disease, Dementia with Lewy Bodies and Parkinson's disease.
3. Seeking US$5 million: Integrated Autoimmune company leading the Next Healthcare Revolution by Uncovering the drivers of autoimmune diseases to advance therapeutic assets.

Hope you found the content useful. We welcome your feedback and queries.